Our Experts
Back to all Experts![Nicholas J. Petrelli, M.D.](http://media-speakerfile-pre.s3.amazonaws.com/images_avatars/9d2cf264e7ce247535252959872e9be61572441199_l.jpg)
Nicholas J. Petrelli, M.D.
Bank of America Endowed Medical Director, Helen F. Graham Cancer Center and Research Institute
Expertise & Research Interests
- Colorectal Cancer
- Cancer Care Management
- Cancer Detection
- Cancer clinical trials
- Surgical Oncology
Education
- MD, Tulane University Medical School
- BA, University of Notre Dame
- Surgical Oncology Fellowship, Roswell Park Cancer Institute
Nicholas J. Petrelli, M.D.
Bank of America Endowed Medical Director, Helen F. Graham Cancer Center and Research Institute
Dr. Nicholas J. Petrelli is a nationally recognized expert on colorectal cancer, joined ChristianaCare as the Bank of America endowed medical director of the Helen F. Graham Cancer Center and Research Institute in August 2001. As medical director, Dr. Petrelli oversees the state’s largest and most technologically advanced cancer program, including cancer detection, diagnosis and treatment. Under his leadership the Graham Cancer Center was selected as a National Cancer Institute Community Oncology Research Program (NCORP) and one of the original 16 NCI Community Cancer Centers Programs (NCCCP).
Dr. Petrelli came to ChristianaCare from one of the nation’s leading NCI Designated Cancer Centers, Roswell Park Cancer Institute in Buffalo, NY, where he led several clinical trials for a promising form of chemotherapy. He has conducted substantial research into the genetics of colorectal cancer and co-authored more than 300 manuscripts in peer-reviewed journals as well as 36 book chapters.
Multimedia
![](https://i.ytimg.com/vi/4N6waPMJOMs/mqdefault.jpg)
![](https://i.ytimg.com/vi/89DBB4SDoME/mqdefault.jpg)
![](https://i.ytimg.com/vi/1Q2-UCG7xwU/mqdefault.jpg)
![](https://i.ytimg.com/vi/xJhMCb_QoYA/mqdefault.jpg)
Experience
Petrelli receives Tilton Award from Medical Society of Delaware
Delaware-developed CRISPR cancer therapy edging closer to human testing
“It will be the first lung cancer clinical trial carried out by a gene editing program embedded in a community cancer center,” Petrelli said. “While our Gene Editing Institute has a great deal of translational research experience, this will be its first study to move scientific discovery toward an IND. And, it will also be the first time that we will be investigating technology that was grown organically at the Gene Editing Institute.”...
ChristianaCare’s Gene Editing Institute takes the next step toward its first investigational drug application for FDA approval to treat lung cancer using CRISPR
- Annals of Surgical Oncology : Associate Editor
- Surgical Oncology Clinics of North America : Editor
- Surgical Oncology : Co-Editor
- Clinical Research Award, 2014 Association of Community Cancer Centers
- American Cancer Society Clinical Oncology Fellowship Award, 1980
- American Cancer Society Clinical Oncology Fellowship Award, 1979